Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Research output: Contribution to journalJournal articlepeer-review

  1. Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approach

    Research output: Contribution to journalJournal articlepeer-review

  2. International severe asthma registry (ISAR): protocol for a global registry

    Research output: Contribution to journalJournal articlepeer-review

  • M Lefort
  • S Sharmin
  • J B Andersen
  • S Vukusic
  • R Casey
  • M Debouverie
  • G Edan
  • J Ciron
  • A Ruet
  • J De Sèze
  • E Maillart
  • H Zephir
  • P Labauge
  • G Defer
  • C Lebrun-Frenay
  • T Moreau
  • E Berger
  • P Clavelou
  • J Pelletier
  • B Stankoff
  • O Gout
  • E Thouvenot
  • O Heinzlef
  • A Al-Khedr
  • B Bourre
  • O Casez
  • P Cabre
  • A Montcuquet
  • A Wahab
  • J P Camdessanché
  • A Maurousset
  • H Ben Nasr
  • K Hankiewicz
  • C Pottier
  • N Maubeuge
  • D Dimitri-Boulos
  • C Nifle
  • D A Laplaud
  • D Horakova
  • E K Havrdova
  • R Alroughani
  • G Izquierdo
  • S Eichau
  • S Ozakbas
  • F Patti
  • M Onofrj
  • A Lugaresi
  • M Terzi
  • P Grammond
  • F Grand'Maison
  • B Yamout
  • A Prat
  • M Girard
  • P Duquette
  • C Boz
  • M Trojano
  • P McCombe
  • M Slee
  • J Lechner-Scott
  • R Turkoglu
  • P Sola
  • D Ferraro
  • F Granella
  • V Shaygannejad
  • J Prevost
  • D Maimone
  • O Skibina
  • K Buzzard
  • A Van der Walt
  • R Karabudak
  • B Van Wijmeersch
  • T Csepany
  • D Spitaleri
  • S Vucic
  • N Koch-Henriksen
  • F Sellebjerg
  • P S Soerensen
  • C C Hilt Christensen
  • P V Rasmussen
  • M B Jensen
  • J L Frederiksen
  • S Bramow
  • H K Mathiesen
  • K I Schreiber
  • H Butzkueven
  • M Magyari
  • T Kalincik
  • E Leray
View graph of relations

BACKGROUND: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.

METHODS: Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed.

RESULTS: Overall, 5,148 relapsing-remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption.

CONCLUSIONS: This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled.

Original languageEnglish
Article number155
JournalBMC Medical Research Methodology
Issue number1
Pages (from-to)155
Publication statusPublished - 30 May 2022

Bibliographical note

© 2022. The Author(s).

    Research areas

  • Fingolimod Hydrochloride/therapeutic use, Humans, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Multiple Sclerosis/drug therapy, Natalizumab/therapeutic use, Treatment Outcome, Multiple sclerosis, Effectiveness, Censoring, Propensity score, Causal contrasts, Positivity assumption, Indication bias

ID: 78361347